India Pharma 2026: Spotlight on Policy, Regulation, AI and CRDMO (See 'Corp Brief') MY Bharat Budget Quest 2026 reaches Grand Culmination Across 17 Zones (See 'Corp Brief') IBC - Multi-state co-operative society can invest in another company, including as resolution applicant under IBC, only if target company is either its subsidiary or engaged in same line of business: SC (See 'Legal Desk') India Pharma highlights Policy Push and Innovation Driving Sectoral Growth (See 'Corp Brief') IBC - Once moratorium is imposed, corporate debtor's pre-CIRP dues cannot be set off against deposit held by creditor: SC (See 'Legal Desk') Ministry of Labour signs MoUs with Porter and Gigin Technologies (See 'Corp Brief') FEMA - SCNs alleging contravention of provisions of FERA merit being quashed, where issued after unjustified delay of 7-10 years, more so where record retention norms generally require preservation for 5-8 years: HC (See 'Legal Desk') Medicine is not just profession, it is a commitment to service of humanity: Murmu (See 'Corp Brief') Misc - Once Freezing Authority identifies properties and forms opinion that they are acquired from illicit source of money derived from drug trafficking, burden of proof shifts entirely onto affected persons to controvert allegations: SAFEMA (See 'Legal Desk') Union Minister jighlights Nari Shakti Vandan Adhiniyam as Transformative Reform (See 'Corp Brief') Bizu Festival Celebrations highlight Cultural Pride and Policy Dialogue on Tribal Development (See 'Corp Brief') India, Kuwait emphasize Dialogue Over Conflict to Secure Energy and Trade Supplies (See 'Corp Brief') Misc - There is no right in borrower to personal hearing by banks before classifying their account as fraud account: SC (See 'Legal Desk') Manohar Lal holds Key Engagements on Infrastructure and Development Cooperation (See 'Corp Brief') CARI Bengaluru gets ISO 15189:2022 Accreditation in Biochemistry (See 'Corp Brief') NI Act - At stage of issuance of process, statutory presumption u/s 139 of NI Act cannot be dislodged in summary manner merely by contending that cheque issued was not for legally enforceable debt: SC (See 'Legal Desk') Barabanki to Bahraich Highway to become Key Cross-Border Trade Lifeline (See 'Corp Brief') Advanced Agriculture fest kicks off in Raisen in MP (See 'Corp Brief') PMLA - Sec 2(1)(u) permits attachment of any property of equivalent value, including properties acquired prior to commission of scheduled offence, which are untraceable: SAFEMA (See 'Legal Desk') NTWB welcomes Jan Vishwas Amendments (See 'Corp Brief') IPR - Controller of Patent would decide whether differences, viewed in knowledge of alleged invention, constitute steps which would have been obvious to ordinary person skilled in art and rule out hindsight approach: HC (See 'Legal Desk') Anand Kumar Pal joins MoF as Chief Cost Adviser (See 'Corp Brief') IPR - Generic disclosure does not, by itself, defeat novelty of specific disclosure; Prior art that teaches away from claimed invention cannot serve as foundation for anticipation: HC (See 'Legal Desk') India-GCC reaffirms commitment to Regional Stability (See 'Corp Brief') IPR - Prior user of trademark has superior rights over subsequent user who holds registration for same or similar mark: HC (See 'Legal Desk') India-Bahrain stresses stability, Supply Chain Resilience and Stronger Economic Ties (See 'Corp Brief') Company Law - Sourcing pre-condition deposit unlawfully from corporate funds in direct violation of Sec 185, or executing settlement agreements without effectuating actual refunds or delivering legally valid & habitable possession, is illegal: SC (See 'Legal Desk') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

India Pharma 2026: Spotlight on Policy, Regulation, AI and CRDMO

Published: Apr 14, 2026

By TIOLCorplaws News Service

NEW DELHI, APR 14, 2026: THE first day of the 9th India Pharma 2026 witnessed four high-impact plenary sessions that brought together policymakers, industry leaders, regulators and technology experts to chart the future of India's pharmaceutical and life sciences ecosystem. The discussions reflected a strong consensus on accelerating innovation through policy support, regulatory transformation and adoption of next-generation technologies.

The inaugural plenary session on "Policy Thrust for Catalysing Innovation", highlighted the urgent need to bridge the gap between policy intent and on-ground execution. Manoj Joshi, Secretary, Department of Pharmaceuticals, emphasised industry-led model for Research and Development, importance of strengthening government lab networks and attuning regulatory model to that of European systems. Rajiv Bahl, Secretary Department of Health Research said though research funding has increased manifold over the last few years, the country needs a Bharat model of R & D with confidence of the market in the innovators and increased trust between industry and academica. Industry leaders echoed the need for increased venture capital participation and co-funding mechanisms to nurture research-driven enterprises, stronger industry-academia integration and underscored the importance of integrated ecosystems to translate early-stage discoveries into global solutions. The session concluded with a strong call to "Discover in India" and position the country as a global innovation hub.

The second plenary session on "Enabling Regulatory Ecosystem to Foster Innovation" focused on creating a predictable, efficient and globally aligned regulatory framework. Dr. Rajeev Singh Raghuvanshi, Drug Controller General of India highlighted the importance of stakeholder consultations in shaping responsive regulatory systems. Industry Experts called for expedited approval pathways, single-window clearance mechanisms and greater global harmonisation to reduce duplication and accelerate patient access. Industry leaders further underlined the need for digital enablement and continuous collaboration between regulators and industry. The session underscored that a future-ready regulatory ecosystem will be critical to unlocking next-generation therapies and strengthening India's global competitiveness.

The third plenary session on "Harnessing AI and Next-Gen Technologies for Disruptive Innovation"   explored the transformative potential of artificial intelligence across the pharmaceutical value chain. Pharma leaders emphasised reimagining processes rather than merely digitising existing systems. They highlighted the growing importance of strong data and technology foundations to enable scalable AI adoption and  stressed the immediate benefits of automation in improving clinical efficiency. The session concluded on a forward-looking note, with experts agreeing that AI will play a pivotal role in accelerating drug discovery, enabling precision medicine and shaping a smarter, innovation-led healthcare ecosystem.

The fourth plenary session on "Unleashing India's CRDMO Potential" brought focus to India's growing role in the global Contract Research, Development and Manufacturing Organization (CRDMO) landscape. The panel noted that India's CRDMO industry, currently valued at around $8 billion, has been growing at a robust pace of 10-12 percent, reflecting strong global outsourcing demand. Industry leaders stressed that speed will be a critical differentiator in scaling India's R&D and manufacturing capabilities, and highlighted the transformative role of AI and digital technologies, including digital twins, in reshaping the CRDMO ecosystem. The session concluded by outlining the strategic priorities required for India to lead the next phase of global growth in complex modalities and outsourced pharma services.

Overall, the plenary sessions on Day 1 of India Pharma 2026 reinforced India's readiness to lead the next phase of global pharmaceutical innovation, driven by policy intent, regulatory agility and technological advancement.

 

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.